Faculty Profiles

Flavio Vincenti, MD

505 Parnassus Avenue
San Francisco, CA 94117

Education and Training

Location Degree or Training Specialty Date
University of California, San Francisco Residency School of Medicine

Featured Videos

Related Web Sites

Awarded Grants

Project Title Project Number Fiscal Year
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts U01AI113362 2021
Recent Articles (238)

Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F. Polyclonal Regulatory T cell Therapy for Control of Inflammation in Kidney Transplants. Am J Transplant. 2017 Jul 04.

Wojciechowski D, Chandran S, Yang J, Sarwal M, Vincenti F. Retrospective Evaluation of the Efficacy and Safety of Belatacept with Thymoglobulin Induction and Maintenance Everolimus: A Single Center Clinical Experience. Clin Transplant. 2017 Jun 29.

Wojciechowski D, Chandran S, Vincenti F. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients. Clin Transplant. 2017 May; 31(5).

Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis. 2016 Nov 23.

Wojciechowski D, Vincenti F. Current status of costimulatory blockade in renal transplantation. Curr Opin Nephrol Hypertens. 2016 Nov; 25(6):583-590.

Wojciechowski D, Vincenti F. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2. Adv Chronic Kidney Dis. 2016 Sep; 23(5):306-311.

Klintmalm GB, Vincenti F, Kirk A. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. Am J Transplant. 2016 Nov; 16(11):3077-3078.

Vincenti F. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jun 30; 374(26):2600-1.

Webber AB, Vincenti F. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed. Transplantation. 2016 Apr; 100(4):836-43.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jan 28; 374(4):333-43.

Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016 Jan; 100(1):184-93.

Sigdel TK, Bestard O, Tran TQ, Hsieh SC, Roedder S, Damm I, Vincenti F, Sarwal MM. A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts. PLoS One. 2015; 10(9):e0138133.

Vincenti F, Silva HT, Busque S, O'Connell PJ, Russ G, Budde K, Yoshida A, Tortorici MA, Lamba M, Lawendy N, Wang W, Chan G. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015 Jun; 15(6):1644-53.

Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, Metes D, Zeevi A, Zeevi A, Gritsch A, Cheeseman J, Macedo C, Peddy R, Medeiros M, Vincenti F, Asher N, Salvatierra O, Shapiro R, Kirk A, Reed EF, Reed E, Sarwal MM. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 2014 Nov; 11(11):e1001759.

Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014 Jul; 25(7):1415-29.

Chandran S, Vincenti F. Clinical aspects: focusing on key unique organ-specific issues of renal transplantation. Cold Spring Harb Perspect Med. 2014 Feb; 4(2).

Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013 Nov; 13(11):2875-83.

Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs. 2013 Sep; 22(9):1193-9.

van Gelder T, Baan C, Vincenti F, Mannon RB. Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma. Transpl Int. 2013 Sep; 26(9):938-48.

Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int. 2013 May; 26(5):471-6.

Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012 Dec 15; 94(11):1117-23.

Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Transplant. 2012 Dec; 17(6):640-7.

Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013 Jan; 13(1):136-45.

Wojciechowski D, Vincenti F. Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biologics. 2012; 6:385-93.

Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67.

Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int. 2012 Oct; 25(10):1059-64.

Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012 Sep; 12(9):2446-56.

Vincenti F. Are calcineurin inhibitors-free regimens ready for prime time? Kidney Int. 2012 Nov; 82(10):1054-60.

Vincenti F. Beyond belatacept: praise and progress for the FDA. Am J Transplant. 2012 Mar; 12(3):513-4.

Wojciechowski D, Vincenti F. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant. 2011 Dec; 16(6):614-9.

Jen KY, Nguyen TB, Vincenti FG, Laszik ZG. C4d/CD34 double-immunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity. Mod Pathol. 2012 Mar; 25(3):434-8.

Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012 Jan; 12(1):210-7.

Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2696-704.

Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov. 2011 Sep; 10(9):655-6.

Wojciechowski D, Vincenti F. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol. 2011 Jun; 23(3):157-64.

Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation. 2011 May 27; 91(10):1057-64.

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011 May 15; 91(9):976-83.

Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011 Jul; 11(7):1444-55.

Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-ß antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011 Jun; 79(11):1236-43.

Humar A. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant. 2011 Jan; 11(1):177-8.

Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010 Dec 27; 90(12):1521-7.

Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601.

Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010 Dec 27; 90(12):1528-35.

Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010 Dec 27; 90(12):1427-31.

Wojciechowski D, Vincenti F. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant. 2010 Dec; 15(6):697-702.

Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D, Dong Y, Garg P. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011 Jan; 11(1):66-76.

Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011 Feb; 6(2):430-9.

Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010 Dec; 56(6):1127-39.

Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80.

Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010 Sep; 21(9):1587-96.

Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010 May; 10(5):1228-37.

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar; 10(3):535-46.

Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar; 10(3):547-57.

Wojciechowski D, Hirose R, Stock P, Vincenti F, Baxter-Lowe LA, Salvatierra O. Kidney transplantation at UCSF: 8,300 transplants and onward. Clin Transpl. 2010; 161-7.

Vincenti F, Cohen SD, Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol. 2010 Jan; 5(1):142-51.

Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010 Feb; 77(4):299-311.

Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009 Aug; 9(8):1936-45.

Bunnapradist S, Vincenti F. Transplantation: To convert or not to convert: lessons from the CONVERT trial. Nat Rev Nephrol. 2009 Jul; 5(7):371-3.

Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis. 2009 Jul; 16(4):226-33.

Murphy B, Vincenti F, Meier-Kriesche HU. The AST's perspective on the proposed kidney allocation system. Am J Transplant. 2009 Jul; 9(7):1500.

Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation. 2009 May 15; 87(9):1360-6.

Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, Posselt AM. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol. 2009 Jul; 4(7):1230-8.

Arias M, Campistol JM, Vincenti F. Evolving trends in induction therapy. Transplant Rev (Orlando). 2009 Apr; 23(2):94-102.

Latek R, Fleener C, Lamian V, Kulbokas E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009 Mar 27; 87(6):926-33.

Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009; 48(5):329-41.

Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008 Oct; 8(10):1972-81.

Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct; 8(10):2086-96.

Halloran PF, Bromberg J, Kaplan B, Vincenti F. Tolerance versus immunosuppression: a perspective. Am J Transplant. 2008 Jul; 8(7):1365-6.

Grinyó J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008 Sep; 21(9):879-91.

Vincenti F, Klintmalm G, Halloran PF. Open letter to the FDA: new drug trials must be relevant. Am J Transplant. 2008 Apr; 8(4):733-4.

Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008 Feb; 8(2):307-16.

Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol. 2008 Feb; 121(2):299-306; quiz 307-8.

Candiano G, Musante L, Petretto A, Bruschi M, Santucci L, Urbani A, Scolari F, Gusmano R, Carraro M, Zennaro C, Vincenti F, Ghiggeri GM. Proteomics of plasma and urine in primary nephrotic syndrome in children. Contrib Nephrol. 2008; 160:17-28.

Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2008 Jan; 8(1):222-7.

Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol. 2007 Jul; 27(4):479-86.

Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7.

Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol. 2007 Dec; 64(6):758-71.

Vincenti F. Costimulation blockade--what will the future bring? Nephrol Dial Transplant. 2007 May; 22(5):1293-6.

Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007 Jun; 7(6):1506-14.

Tomlanovich SJ, Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol. 2007 Mar; 2(2):198-9.

Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi G, Pavone B, Del Boccio P, Galliano M, Urbani A, Scolari F, Vincenti F, Ghiggeri GM. Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol. 2007 Mar; 18(3):799-810.

Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007 Mar; 7(3):560-70.

Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med. 2007; 58:347-58.

Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, Vincenti F. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006 Oct 27; 82(8):1004-12.

Brennan TV, Fuller TF, Vincenti F, Chan S, Chang CK, Bostrom A, Zlatunich JK, Tomlanovich SJ, Feng S. Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care. Am J Transplant. 2006 Oct; 6(10):2429-35.

Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis. 2006 Aug; 26(3):201-10.

Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, González-Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int. 2006 Jun; 19(6):446-57.

Vincenti F. Antibodies come back to the forefront in transplantation. Clin J Am Soc Nephrol. 2006 May; 1(3):399.

Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu YM, Katz SM, Akalin E, Esterl R, Gugliuzza K, Shihab F, Jordan S, Jonsson J, Molmenti E, Barbeito R. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation. 2005 Oct 15; 80(7):910-6.

Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S221-34.

Aziz S, Callen PW, Vincenti F, Hirose R. Rapidly developing nephrocalcinosis in a patient with end-stage liver disease who received a domino liver transplant from a patient with known congenital oxalosis. J Ultrasound Med. 2005 Oct; 24(10):1449-52.

Vincenti F. Current use and future trends in induction therapy. Saudi J Kidney Dis Transpl. 2005 Oct-Dec; 16(4):506-13.

Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25; 353(8):770-81.

Vincenti F. A drug of the past, a lesson for the future. Pediatr Transplant. 2005 Jun; 9(3):267-8.

Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005 Jun; 19(3):291-8.

Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005 Jun; 5(6):1179-85.

Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. Transplant Proc. 2005 Mar; 37(2):1001-4.

Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant. 2005 Feb; 19(1):130-6.

Vincenti F, Rostaing L. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. Contemp Clin Trials. 2005 Feb; 26(1):17-24.

Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol. 2005; 146:22-9.

Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant. 2005 Jan; 5(1):157-66.

Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant. 2004 Dec; 4(12):2132-4.

Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transpl Int. 2004 Sep; 17(8):395-401.

Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004 Sep-Oct; 8(5):231-3.

Vincenti F. A decade of progress in kidney transplantation. Transplantation. 2004 May 15; 77(9 Suppl):S52-61.

Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant. 2004 May; 19(5):1036-40.

Vincenti F, Brennan TV, Fuller TF, Feng S. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys. Transplant Proc. 2004 Mar; 36(2 Suppl):50S-53S.

Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Papadimitriou JC, Weir MR, Wali RK. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004 Jan 15; 77(1):131-3.

Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant. 2003 Dec; 17(6):511-7.

Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation. 2003 Jul 15; 76(1):190-5.

Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003 Jul; 3(7):835-45.

Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003 Jul; 14(7):1940-8.

Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc. 2003 May; 35(3 Suppl):183S-186S.

Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant. 2003 Mar; 3(3):306-11.

Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol. 2003 Mar; 55(1):57-66.

Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant. 2003 Jan; 3(1):50-2.

Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002 Nov; 2(10):898-903.

Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002 Mar 15; 73(5):775-82.

Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002 Mar; 42(3):304-11.

Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc. 2001 Nov-Dec; 33(7-8):3169-71.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001 Sep 15; 72(5):839-45.

Bumgardner GL, Ramos E, Lin A, Vincenti F. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 2001 Aug 27; 72(4):642-7.

Vincenti F. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen. Transplant Proc. 2001 Jun; 33(4 Suppl):11S-18S.

Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001 May 15; 71(9):1282-7.

Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1011-2.

Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1000-1.

Vincenti F. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc. 2001 Feb-Mar; 33(1-2):1019-20.

Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 2000 Dec 27; 70(12):1707-12.

Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant. 2000 Dec; 14(6):550-4.

Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass N, Facklam D, Mekki Q. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol. 2000 May; 40(5):527-32.

Korsun A, Vincenti F, Ruck D, Whitelaw N, Ladoulis C, Whitelaw G. The role of daclizumab in balancing resources for inpatient and outpatient transplant services. Prog Transplant. 2000 Mar; 10(1):21-4.

Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int. 2000; 13(2):151-9.

Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation. 1999 Sep 15; 68(5):635-41.

Vincenti F. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Transplant Proc. 1999 Sep; 31(6):2206-7.

Vincenti F. Potential of daclizumab in solid organ transplantation. BioDrugs. 1999 May; 11(5):333-41.

Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc. 1999 Feb-Mar; 31(1-2):1246-8.

Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F, George V. Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. Transplant Proc. 1999 Feb-Mar; 31(1-2):223-4.

Hirose R, Vincenti F. Review of transplantation--1999. Clin Transpl. 1999; 295-315.

Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation. 1998 Dec 27; 66(12):1736-40.

Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc. 1998 Aug; 30(5):2155-8.

Bumgardner GL, Amend WC, Ascher NL, Vincenti FG. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation. 1998 Apr 27; 65(8):1053-60.

Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998 Jan 15; 338(3):161-5.

Bretan PN, Freise C, Goldstein R, Osorio R, Tomlanovich S, Amend W, Mathur V, Vincenti F. Selection strategies for successful utilization of less than 15.kg pediatric donor kidneys. Transplant Proc. 1997 Dec; 29(8):3274-5.

Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15; 63(7):977-83.

Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. Transplant Proc. 1997 Feb-Mar; 29(1-2):304-5.

Bretan PN, Friese C, Goldstein RB, Osorio RW, Tomlanovich S, Amend W, Mathur V, Vincenti F. Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys--long term experiences with 40 transplants. Transplantation. 1997 Jan 27; 63(2):233-7.

Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 1997 Jan 15; 63(1):33-8.

Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996 Oct 15; 62(7):900-5.

Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9.

Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation. 1996 Jun 15; 61(11):1576-81.

Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996 Apr 4; 334(14):878-83.

Stock PG, Lantz M, Light S, Vincenti F. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc. 1996 Apr; 28(2):915-6.

Vincenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study. Transplantation. 1996 Feb 27; 61(4):573-7.

Lam PW, Wachs ME, Somberg KA, Vincenti F, Lake JR, Ferrell LD. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 1996 Feb 15; 61(3):378-81.

Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJ. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection. Transplantation. 1995 Dec 15; 60(11):1215-9.

Orloff SL, Stempel CA, Wright TL, Tomlanovich SJ, Amend WJ, Stock PG, Melzer JS, Vincenti F. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant. 1995 Apr; 9(2):119-24.

Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc. 1995 Feb; 27(1):809-11.

Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation. 1995 Jan 27; 59(2):230-4.

Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994 Apr; 23(4):574-81.

Vincenti FG, Vasconcelos M, Birnbaum JL, Tomlanovich SJ, Amend WJ, Melzer JS, Snyder JP. Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc. 1993 Apr; 25(2 Suppl 1):57-9.

Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation. 1993 Mar; 55(3):674-5.

Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation. 1993 Feb; 55(2):273-6.

Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992 Apr; 92(4):375-83.

Krams SM, Falco DA, Villanueva JC, Rabkin J, Tomlanovich SJ, Vincenti F, Amend WJ, Melzer J, Garovoy MR, Roberts JP. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation. 1992 Jan; 53(1):151-6.

Vincenti F, Weber P, Kuo G, Forsell J, Hunt S, Melzer J, Salvatierra O, Stempel C. Hepatitis C virus in cadaver organ donors: prevalence and risk of transmission to transplant recipients. Transplant Proc. 1991 Oct; 23(5):2651-2.

Salvatierra O, McVicar J, Melzer J, Amend W, Vincenti F, Tomlanovich S, Husing R, Rabkin J, Garovoy M. Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol. Transplant Proc. 1991 Feb; 23(1 Pt 2):1024-6.

Stempel C, Lake J, Ferrell L, Tomlanovich S, Amend W, Salvatierra O, Vincenti F. Effect of cyclosporine on the clinical course of HBsAg-positive renal transplant patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):1251-2.

Vincenti F, Biava C, Tomlanovitch S, Amend WJ, Garovoy M, Melzer J, Feduska N, Salvatierra O. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation. 1989 Apr; 47(4):595-8.

Melzer JS, Husing R, Lou C, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. Successful management of the highly sensitized renal allograft recipient. Transplant Proc. 1989 Feb; 21(1 Pt 1):751-3.

Tomlanovich SJ, Sabatte-Caspillo J, Melzer J, Amend W, Vincenti F, Feduska N, Salvatierra O. The incidence and impact of herpes simplex virus infections in the first month following renal transplantation. Transplant Proc. 1989 Feb; 21(1 Pt 2):2091-2.

Lockard-Marduel A, Gumbert M, Tomlanovich S, Amend W, Vincenti F, Schralla P, Melzer J, Feduska NJ, Salvatierra O, Garovoy MR. Immunologic alterations induced by donor-specific transfusion. Transplant Proc. 1989 Feb; 21(1 Pt 1):1171-2.

Feduska NJ, Melzer JS, Amend WJ, Vincenti F, Tomlanovich SJ, Garovoy M, Husing R, Salvatierra O. Cyclosporine provides better success rates for both higher- and lower-risk cadaveric kidney transplant recipients. Transplant Proc. 1988 Jun; 20(3 Suppl 3):102-9.

Tomlanovich S, Vincenti F, Amend W, Biava C, Melzer J, Feduska N, Salvatierra O. Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease after renal transplantation? Transplant Proc. 1988 Jun; 20(3 Suppl 4):285-8.

Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Lou C, Salvatierra O. How to improve results for second renal allografts. Transplant Proc. 1988 Jun; 20(3 Suppl 3):176-9.

Hricak H, Terrier F, Marotti M, Engelstad BL, Filly RA, Vincenti F, Duca RM, Bretan PN, Higgins CB, Feduska N. Posttransplant renal rejection: comparison of quantitative scintigraphy, US, and MR imaging. Radiology. 1987 Mar; 162(3):685-8.

Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. Has cyclosporine really relegated pretransplant blood transfusions to therapeutic obsolescence? Transplant Proc. 1987 Feb; 19(1 Pt 3):1971-3.

Salvatierra O, Melzer J, Vincenti F, Amend WJ, Tomlanovich S, Potter D, Husing R, Garovoy M, Feduska NJ. Donor-specific blood transfusions versus cyclosporine--the DST story. Transplant Proc. 1987 Feb; 19(1 Pt 1):160-6.

Feduska NJ, Perkins HA, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Garovoy M, Salvatierra O. Observations relating to the incidence of the acquired immune deficiency syndrome and other possibly associated conditions in a large population of renal transplant recipients. Transplant Proc. 1987 Feb; 19(1 Pt 3):2161-6.

Linkowski GD, Warvariv V, Filly RA, Vincenti F. Sonography in the diagnosis of acute renal allograft rejection and cyclosporine nephrotoxicity. AJR Am J Roentgenol. 1987 Feb; 148(2):291-5.

Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation. 1987 Jan; 43(1):61-4.

Bachman U, Biava C, Amend W, Feduska N, Melzer J, Salvatierra O, Vincenti F. The clinical course of IgA-nephropathy and Henoch-Schönlein purpura following renal transplantation. Transplantation. 1986 Nov; 42(5):511-5.

Hoddick W, Filly RA, Backman U, Callen PW, Vincenti F, Hricak H, Mahony BS, Amend W. Renal allograft rejection: US evaluation. Radiology. 1986 Nov; 161(2):469-73.

Feduska NJ, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Salvatierra O. Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months. Transplant Proc. 1986 Apr; 18(2 Suppl 1):136-40.

Stabile C, Vincenti F, Garovoy M, Duca R, Melzer J, Feduska NJ, Salvatierra O, Amend WJ. Is a "low" dose of prednisone better than a "high" dose at the time of renal transplantation? Braz J Med Biol Res. 1986; 19(3):355-66.

Salvatierra O, Melzer J, Potter D, Garovoy M, Vincenti F, Amend WJ, Husing R, Hopper S, Feduska NJ. A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation. 1985 Dec; 40(6):654-9.

Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S. Pharmacokinetics of sulfisoxazole in renal transplant patients. Antimicrob Agents Chemother. 1985 Oct; 28(4):535-9.

Feduska NJ, Melzer J, Amend W, Vincenti F, Duca R, Garovoy M, Hopper S, Salvatierra O. Dramatic improvement in the success rate for renal transplants in diabetic recipients with donor-specific transfusions. Transplantation. 1984 Dec; 38(6):704-8.

Feduska NJ, Amend WJ, Vincenti F, Melzer JS, Duca R, Garovoy MR, Salvatierra O. Peptic ulcer disease in kidney transplant recipients. Am J Surg. 1984 Jul; 148(1):51-7.

Vincenti F, Arnaud SB, Recker R, Genant H, Amend WJ, Feduska NJ, Salvatierra O. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int. 1984 Apr; 25(4):677-82.

Vincenti F, Amend WJ, Kaysen G, Feduska N, Birnbaum J, Duca R, Salvatierra O. Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects. Transplantation. 1983 Dec; 36(6):626-9.

Salvatierra O, Vincenti F, Amend WJ, Garovoy MR, Potter D, Feduska NJ. The role of blood transfusions in renal transplantation. Urol Clin North Am. 1983 May; 10(2):243-52.

Benet LZ, Smith DE, Lin ET, Vincenti F, Gambertoglio JG. Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc. 1983 Apr; 42(6):1695-8.

Berger BE, Vincenti F, Biava C, Amend WJ, Feduska N, Salvatierra O. De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation. 1983 Apr; 35(4):315-9.

O'Connor DT, Barg AP, Amend W, Vincenti F. Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function. Am J Med. 1982 Oct; 73(4):475-81.

Feduska NJ, Amend WJ, Vincenti F, Duca R, Salvatierra O. Blood transfusions before and on the day of transplantation: effects on cadaver graft survival. Transplant Proc. 1982 Jun; 14(2):302-4.

Salvatierra O, Iwaki Y, Vincenti F, Amend W, Terasaki P, Garovoy M, Duca R, Hopper S, Feduska N. Update of the University of California at San Francisco experience with donor-specific blood transfusions. Transplant Proc. 1982 Jun; 14(2):363-6.

Gambertoglio JG, Frey FJ, Holford NH, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O, Amend WJ. Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int. 1982 Apr; 21(4):621-6.

Vincenti F, Amend WJ, Feduska NJ, Salvatierra O. Blood transfusions and kidney transplantation. Arch Intern Med. 1982 Apr; 142(4):680-1.

Amend WJ, Vincenti F, Duca R, Feduska NJ, Cochrum K, Potter D, Salvatierra O. Prognostic features of early renal transplant rejections. Am J Kidney Dis. 1982 Mar; 1(5):281-7.

Vincenti F, Amend WJ, Feduska NJ, Salvatierra O. Septic arthritis following renal transplantation. Nephron. 1982; 30(3):253-6.

Salvatierra O, Iwaki Y, Vincenti F, Amend W, Potter D, Opelz G, Terasaki P, Duca R, Hopper S, Feduska N. Incidence, characteristics, and outcome of recipients sensitized after donor-specific blood transfusions. Transplantation. 1981 Dec; 32(6):528-31.

Feduska NJ, Vincenti F, Amend W, Iwaki Y, Opelz G, Terasaki P, Duca R, Hopper S, Salvatierra O. An alternative to cadaver kidney transplants for patients with insulin-dependent diabetes mellitus. Transplantation. 1981 Dec; 32(6):517-21.

Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Levin B, Sampson D, Feduska N, Salvatierra O. Improved graft survival following donor-specific blood transfusions. Transplant Proc. 1981 Sep; 13(3):1657-61.

Cogan MG, Sargent JA, Yarbrough SG, Vincenti F, Amend WJ. Prevention of prednisone-induced negative nitrogen balance. Effect of dietary modification on urea generation rate in patients on hemodialysis receiving high-dose glucocorticoids. Ann Intern Med. 1981 Aug; 95(2):158-61.

Salvatierra O, Amend W, Vincenti F, Potter D, Stoney R, Duca R, Feduska N. 1,500 renal transplants at one center: evolution of a strategy for optimal success. Am J Surg. 1981 Jul; 142(1):14-20.

Smith DE, Gambertoglio JG, Vincenti F, Benet LZ. Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther. 1981 Jul; 30(1):105-13.

Amend WJ, Vincenti F, Feduska NJ, Salvatierra O, Johnston WH, Jackson J, Tilney N, Garovoy M, Burwell EL. Recurrent systemic lupus erythematosus involving renal allografts. Ann Intern Med. 1981 Apr; 94(4 pt 1):444-8.

Vincenti F, Hattner R, Amend WJ, Feduska NJ, Duca RM, Salvatierra O. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA. 1981 Mar 6; 245(9):930-3.

Feduska NJ, Amend WJ, Vincenti F, Perkins HA, Opelz G, Terasaki PI, Iwaki Y, Duca R, Dodge D, Salvatierra O. Graft survival with high levels of cytotoxic antibodies. Transplant Proc. 1981 Mar; 13(1 Pt 1):73-80.

Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Feduska N, Salvatierra O. Improved graft survival with donor-specific transfusion pretreatment. Transplant Proc. 1981 Mar; 13(1 Pt 1):190-3.

Salvatierra O, Amend W, Vincenti F, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Hanes D, Cochrum KC, Hopper S, Feduska NJ. Pretreatment with donor-specific blood transfusions in related recipients with high MLC. Transplant Proc. 1981 Mar; 13(1 Pt 1):142-9.

Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O, Amend WJ. Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. J Clin Endocrinol Metab. 1980 Sep; 51(3):561-5.

Vincenti F, Amend W, Feduska NJ, Duca RM, Salvatierra O. Improved outcome following renal transplantation with reduction in the immunosuppression therapy for rejection episodes. Am J Med. 1980 Jul; 69(1):107-12.

Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med. 1980 Mar; 68(3):363-9.

Pearson JC, Amend WJ, Vincenti FG, Feduska NJ, Salvatierra O. Post-transplantation pyelonephritis: factors producing low patient and transplant morbidity. J Urol. 1980 Feb; 123(2):153-6.

Salvatierra O, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Cochrum K, Hanes D, Stoney RJ, Feduska NJ. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg. 1980; 192(4):543-52.

Hopper S, Feduska N, Vincenti F, Amend W, Salvatierra O. The organization of a successful donor-specific transfusion protocol in related recipients with high MLC. Proc Clin Dial Transplant Forum. 1980; 10:272-6.

Cochrum KC, Hanes D, Potter D, Vincenti F, Amend W, Feduska N, Perkins H, Salvatierra O. Donor-specific blood transfusions in HLA-D-disparate one-haplotype-related allografts. Transplant Proc. 1979 Dec; 11(4):1903-7.

Spring DB, Salvatierra O, Palubinskas AJ, Amend WJ, Vincenti FG, Feduska NJ. Results and significance of angiography in potential kidney donors. Radiology. 1979 Oct; 133(1):45-7.

Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med. 1979 Sep; 91(3):412-3.

Salvatierra O, Feduska NJ, Vincenti F, Duca R, Potter D, Nolan J, Cochrum KC, Amend WJ. Analysis of costs and outcomes of renal transplantation at one center. Its implications. JAMA. 1979 Apr 6; 241(14):1469-73.

Cochrum K, Hanes D, Van Speybroeck J, Perkins H, Ferrone S, Indeveri F, Amend W, Vincenti F, Feduska N, Salvatierra O. HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival. Transplant Proc. 1979 Mar; 11(1):404-10.

Speybroeck JV, Feduska N, Amend W, Vincenti F, Cochrum K, Salvatierra O. The influence of donor age on graft survival. Am J Surg. 1979 Mar; 137(3):374-7.

Feduska NJ, Collins GM, Amend WJ, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O. Comparative study of albumin solution and cryoprecipitated plasma for renal preservation: a preliminary report. Transplant Proc. 1979 Mar; 11(1):472-7.

Vincenti F, Amend W, Feduska N, Duca R, Salvatierra O. Pretransplant cytotoxic antibodies do not segregate kidney transplant recipients into responder and non-responder groups. Proc Eur Dial Transplant Assoc. 1979; 16:419-25.

Feduska NJ, Vincenti F, Amend WJ, Duca R, Cochrum K, Salvatierra O. Do blood transfusions enhance the possibility of a compatible transplant? Transplantation. 1979 Jan; 27(1):35-8.

Vincenti F, Duca RM, Amend W, Perkins HA, Cochrum KC, Feduska NJ, Salvatierra O. Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival. N Engl J Med. 1978 Oct 12; 299(15):793-8.

Cochrum KC, Haynes DM, Salvatierra O, Feduska NJ, Vincenti F, Van Speybroeck J. Leukocyte migration inhibitory factor (LIF) as an indicator of presensitization and allograft survival. Transplant Proc. 1978 Jun; 10(2):455-8.

Feduska NJ, Belzer FO, Stieper KW, Duca RM, Mitchell JW, Vincenti F, Cochrum KC, Salvatierra O. A ten year experience with cadaver kidney preservation using cryoprecipitated plasma. Am J Surg. 1978 Mar; 135(3):356-61.

Vincenti F, Amend W, Feduska N, Maglio M, Axel L, Cochrum K, Salvatierra O. The effect of hypothermic pulsatile perfusion on glomerular epithelial surface structures studied by scanning electron microscopy. Trans Am Soc Artif Intern Organs. 1978; 24:257-60.

Feduska NJ, Amend WJ, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O. Cadaver kidney transplantation provided from one center within a large geographical region. Trans Am Soc Artif Intern Organs. 1978; 24:270-7.

Denes AE, Berquist KR, Fields HA, Vincenti F. Hepatitis-B reactivation after renal transplantation. Lancet. 1977 Jun 18; 1(8025):1314.

Vincenti FG, Heymsfield S. Reversible malignant hypertension and azotemia due to urethral stricture. Arch Intern Med. 1977 Mar; 137(3):370-2.

Amend W, Vincenti F, Covey C, Epstein W, Feduska N, Salvatierra O. Renal transplantation in systemic lupus erythematosus. Proc Clin Dial Transplant Forum. 1977; 7:18-22.

Hajjar ET, Vincenti F, Salti IS. Gluten-induced enteropathy. Osteomalacia as its principal manifestation. Arch Intern Med. 1974 Sep; 134(3):565-6.

Vincenti F, Hajjar ET, Salti IS. Tumorous hyperparathyroidism in hypophosphatemic vitamin D--resistant rickets. J Med Liban. 1973; 26(6):583-94.

Vincenti F, Birbari A, Rizk G. Renal vein renin in hypertension. Diagnostic and therapeutic implications. J Med Liban. 1973; 26(1):9-16.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.